CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Grant or award Sinha Vikas acquired 100,000 shares (grant or award)
- 4 Grant or award General Counsel acquired 15,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 100,000 shares (grant or award)
- 4 Open-market sale Chief Commercial Officer sold 15,590 shares at $8.30 ($129,473)
- 4 Grant or award Chief Accounting Officer acquired 20,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Sinha Vikas acquired 3,253,796 shares (grant or award)
- 4 Grant or award Director acquired 3,253,796 shares (grant or award)
- 4 Grant or award Director acquired 8,152,247 shares (grant or award)
- 4 Grant or award Director acquired 3,253,796 shares (grant or award)
- 4 Grant or award Director acquired 3,253,796 shares (grant or award)
- 4 Open-market sale Atillasoy Ercem sold 1,533 shares at $5.38 ($8,245)
- 4 Open-market sale Director sold 4,227 shares at $5.33 ($22,528)
- 4 Open-market sale Sinha Vikas sold 1,432 shares at $5.21 ($7,467)
- 4 Open-market sale Atillasoy Ercem sold 563 shares at $5.21 ($2,936)
- 4 Open-market sale Chief Commercial Officer sold 1,058 shares at $5.21 ($5,517)
- 4 Grant or award Chief Accounting Officer acquired 10,500 shares (grant or award)
- 4 Grant or award General Counsel acquired 14,000 shares (grant or award)
- 4 Grant or award Director acquired 29,400 shares (grant or award)
Page 11 of 19 · 363 filings